Kimia Biosciences Ltd
Kimia Biosciences Ltd (KIMIABL) last traded at ₹27.3, a market capitalisation of ₹129 crore, on a P/E of 17.9. Over the past 52 weeks the stock has ranged between ₹23.2 and ₹43.3. Kimia Biosciences Ltd last reported results for the quarter ended Jun 2026, with sales of ₹20.72 crore and net profit of ₹0.36 crore. Figures are as of 25 Aug 2026 and are not real time.
Kimia Biosciences Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Kimia Biosciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹20.72 cr, down 12.1% from ₹23.58 cr a year earlier. Net profit was ₹0.36 cr, down 40.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 28.18 | 30.1 | 38.24 | 23.58 | 34 | 30.1 | 27.2 | 20.72 |
| Expenses | 24.81 | 25.1 | 30.06 | 21.05 | 31.48 | 23.54 | 24.54 | 18.37 |
| Operating profit | 3.37 | 5 | 8.18 | 2.53 | 2.52 | 6.56 | 2.66 | 2.35 |
| OPM % | 11.96% | 16.61% | 21.39% | 10.73% | 7.41% | 21.79% | 9.78% | 11.34% |
| Other income | 0.37 | 0.42 | 0.44 | 0.85 | -0.33 | 0.1 | 1.01 | 0.08 |
| Interest | 1.04 | 1.01 | 1.4 | 1.75 | 0.27 | 0.75 | 0.75 | 0.83 |
| Depreciation | 0.79 | 0.82 | 0.88 | 0.94 | 0.97 | 0.85 | 1.16 | 1.11 |
| Profit before tax | 1.91 | 3.59 | 6.34 | 0.69 | 0.95 | 5.06 | 1.76 | 0.49 |
| Tax % | 15.71% | -27.30% | 68.61% | 13.04% | -7.37% | -7.71% | 78.98% | 26.53% |
| Net profit | 1.61 | 4.57 | 1.99 | 0.6 | 1.02 | 5.44 | 0.37 | 0.36 |
| EPS (₹) | 0.34 | 0.97 | 0.42 | 0.13 | 0.22 | 1.15 | 0.08 | 0.08 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Kimia Biosciences Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 133 | 125 | 129 | 105 | 119 | 115 | 112 |
| Operating profit | 8 | 1 | -5 | -0 | 20 | 14 | 14 |
| OPM % | 6% | 0.5% | -3.9% | -0.5% | 17% | 12% | 13% |
| Net profit | 5 | -4 | -9 | -5 | 10 | 7 | 7 |
| EPS (₹) | 1.08 | -0.78 | -1.98 | -1.12 | 2.03 | 1.57 | 1.53 |
TTM is the trailing twelve months to the most recent quarter.
Kimia Biosciences Ltd growth and returns
- 10 Years
- 90%
- 5 Years
- -3%
- 3 Years
- -4%
- TTM
- -7%
- 10 Years
- 14%
- 5 Years
- 8%
- 3 Years
- 43%
- TTM
- -18%
- 10 Years
- 13%
- 5 Years
- -8%
- 3 Years
- -7%
- 1 Year
- -27%
- 10 Years
- %
- 5 Years
- -1%
- 3 Years
- 54%
- Last Year
- 54%
Kimia Biosciences Ltd shareholding pattern
Promoters held 74.94% at Jun 2026, broadly unchanged since Jun 2025. DIIs 0.38%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% |
| DIIs | 0.38% | 0.38% | 0.38% | 0.38% | 0.38% | 0.38% | 0.38% | 0.38% |
| Public | 24.67% | 24.68% | 24.67% | 24.68% | 24.68% | 24.68% | 24.68% | 24.68% |
| No. of shareholders | 12,179 | 12,231 | 12,278 | 12,200 | 12,616 | 12,751 | 12,775 | 12,775 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Kimia Biosciences Ltd corporate filings
- Newspaper publication unaudited Financial Results for the Quarter Ended 30 June, 2026Company Updatemedium impact
Cruxal's analysis: Kimia Biosciences Limited reported its standalone financial results for the quarter ended…
Read the full analysis - Pursuant to Regulation 33 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we have enclosed herewith: 1. Unaudited ....Board Meetinghigh impact
Cruxal's analysis: Kimia Biosciences Limited reported a significant decline in financial performance for the…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Kimia Biosciences Ltd
Cruxal reads every Kimia Biosciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.